NYSEAMERICAN:IBIOIbio Stock Price, Forecast & News

$0.93

+0.06 (+6.86 %)

(As of 04/9/2020 04:00 PM ET)

Add

Compare

Today's Range

$0.90

Now: $0.93▼

$1.05

50-Day Range N/A

52-Week Range

$0.05

Now: $0.93▼

$3.40

Volume18.28 million shs

Average Volume26.28 million shs

Market Capitalization$94.83 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

iBio, Inc., a biotechnology company, provides product development and manufacturing services to clients, collaborators, and third-party customers in the United States and internationally. The company's services cover the stages of product selection, regulatory approval, and commercial product launch. Its lead therapeutic candidate is IBIO-CFB03 for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and other fibrotic diseases. It is also developing vaccine candidates for third parties. The company has collaboration agreements with ONEWAY Diagnostica; AzarGen Biotechnologies (Pty) Ltd; The Texas A&M University System; and Fraunhofer Center for Molecular Biotechnology, as well as strategic relationship with CC-Pharming Ltd. In addition, it offers a range of product and process development, analytical, and manufacturing services. iBio, Inc. is headquartered in New York, New York.

Beat the Market (BTM) Rank^™

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Ibio.

3.1 Community Rank

Outperform Votes
Ibio has received 150 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Ibio has received 93 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Ibio has received 61.73% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Ibio and other stocks. Vote “Outperform” if you believe IBIO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe IBIO will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Ibio does not currently pay a dividend.
Dividend Growth
Ibio does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Ibio insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

Overall Beat the Market Rank^™

0.62 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN

Industry Biotechnology

Sub-IndustryN/A

SectorMedical

Current SymbolNYSEAMERICAN:IBIO

Previous SymbolNASDAQ:IBIO

CUSIPN/A

CIK1420720

Webhttp://www.ibioinc.com/

Phone+1-302-3550650

Debt

Debt-to-Equity RatioN/A

Current RatioN/A

Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book ValueN/A

Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Employees54

Outstanding Shares101,444,000

Market Cap$94.83 million

Next Earnings Date5/8/2020 (Estimated)

OptionableNot Optionable

Receive IBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for IBIO and its competitors with MarketBeat's FREE daily newsletter.

Ibio (NYSEAMERICAN:IBIO) Frequently Asked Questions

When is Ibio's next earnings date?

Ibio is scheduled to release its next quarterly earnings announcement on Friday, May 8th 2020. View our earnings forecast for Ibio.

How were Ibio's earnings last quarter?

Ibio Inc (NYSEAMERICAN:IBIO) released its earnings results on Friday, February, 14th. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter. The biotechnology company had revenue of $0.31 million for the quarter. View Ibio's earnings history.

When did Ibio's stock split? How did Ibio's stock split work?

Ibio shares reverse split before market open on Monday, June 11th 2018. The 1-10 reverse split was announced on Thursday, May 31st 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 8th 2018. An investor that had 100 shares of Ibio stock prior to the reverse split would have 10 shares after the split.

Has Ibio been receiving favorable news coverage?

News articles about IBIO stock have been trending very negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Ibio earned a coverage optimism score of -3.3 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutIbio.

Who are some of Ibio's key competitors?

Some companies that are related to Ibio include CEL-SCI (CVM), Cel-Sci (CVM), Silence Therapeutics (SLN), Starpharma (SPL), ProMetic Life Sciences (PLI), Pfenex (PFNX), Paradigm Biopharmaceuticals (PAR), TELIX Pharmaceutical (TLX), Pfenex (PFNX), Emblem (EMC), Ergomed (ERGO), Helix Biopharma (HBP), Bioventix (BVXP), Horizon Discovery Group (HZD) and Resverlogix (RVX).

What other stocks do shareholders of Ibio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ibio investors own include Inovio Pharmaceuticals (INO), Tonix Pharmaceuticals (TNXP), FuelCell Energy (FCEL), Onconova Therapeutics (ONTX), Vaxart (VXRT), Biocept (BIOC), Co-Diagnostics (CODX), Novavax (NVAX), VBI Vaccines (VBIV) and Inpixon (INPX).

Who are Ibio's key executives?

Ibio's management team includes the following people:

Mr. Robert B. Kay, Exec. Chairman & CEO (Age 79)
Mr. Robert L. Erwin, Pres (Age 66)
Mr. James P. Mullaney CPA, CPA, Chief Financial Officer (Age 48)
Mr. Terence E. Ryan, Chief Scientific Officer (Age 64)
Dr. Renato Lobo, Chief Medical Officer

What is Ibio's stock symbol?

Ibio trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "IBIO."

How do I buy shares of Ibio?

Shares of IBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Ibio's stock price today?

One share of IBIO stock can currently be purchased for approximately $0.93.

How big of a company is Ibio?

Ibio has a market capitalization of $94.34 million. Ibio employs 54 workers across the globe. View additional information about Ibio.

What is Ibio's official website?

The official website for Ibio is http://www.ibioinc.com/.

How can I contact Ibio?

Ibio's mailing address is 600 Madison Ave Ste 1601, NEW YORK, NY 10022-1737, United States. The biotechnology company can be reached via phone at +1-302-3550650.

This page was last updated on 4/9/2020 by MarketBeat.com Staff